Patients with the 1p/19q co-deletion (n=13) had a median survival of 74 months (95% CI 21-127 months), while those without the co-deletion (n=7) had a median survival of 60 months (95% CI 47-74 months) although the difference was not significant to the small size of this preliminary dataset (p=0.782).

**DISCUSSION**

Our review of anaplastic oligodendroglial tumours treated "pre-1p19q stratification" indicates our clinical outcomes are comparable with other published reports. This study serves as an important baseline for future comparative studies following the recent change in practice. It is also a requirement of ongoing national cancer peer review to report regional outcomes for patients and benchmark them with the national standards. Furthermore, with the emergence of molecular profiling of all gliomas as a mandatory requirement in the forthcoming amended WHO diagnostic criteria, it will be important to have access to a regional service that can provide molecular profile in tandem with routine histology reports. Not only will this ensure our patients receive the same standard of care as other UK neuro-oncology centres but also minimise anxiety associated with delays in molecular profile reports returning from outside institutions.

The authors have no conflict of interest apart from the pressing clinical need of a regional molecular profiling service.

Cathal Hannan, Dr Shahnaz Al-Rashid, Dr. Brian Herron, Dr. David Conkey, Dr. Jacqui Harney, Julie Lyness, Joanne Moss, Dr. Tom Flannery.

Regional Neuro-oncology Multidisciplinary Team, Belfast Health & Social Care Trust.

Centre for Cancer Research & Cell Biology, Queen’s University Belfast.

Correspondence to Tom Flannery
tom.flannery@belfasttrust.hscni.net

**REFERENCES**

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO Classification of tumours of the central nervous system. *Acta Neuropathol*. 2007; 114(2):97-109.

2. Weller M, Stupp R, Hegi ME, van den Bent M, Tom J, Sanson M, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. *Neuro Oncol*. 2012; 14(Suppl 4):iv100-8.

3. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. *J Clin Oncol*. 2013; 31(3):344-50.

4. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. *J Clin Oncol*. 2013; 31(3):337-43.

5. Sepulveda Sanchez JM, Martinez Montero JC, Diez-Lobato R, Hernandez-Lain A, Cabello A, Ramos A, et al. Classification of oligodendroglial tumours based on histopathology criteria is a significant predictor of survival – clinical, radiological and pathologic long-term follow-up analysis. *Clin Neuropathol*. 2009; 28(1):11-20.
DISCUSSION:
Foreign body embolisation is a rare complication of penetrating trauma from firearms. The incidence of bullet embolisation after penetrating injury is estimated to be 0.3 – 1% (1). Patients may be asymptomatic, however the development of complications such as distal limb ischaemia, endocarditis, pulmonary embolism or stroke should prompt consideration of emboli. The diagnosis of bullet embolisation should also be considered when there is a discrepancy between the number of penetrating wounds and the foreign bodies identified, the location of the bullet does not match that which would be expected by the trajectory or when migration of bullets are demonstrated on serial radiographs.

The most common destination of venous emboli is the right ventricle followed by the pulmonary artery. Embolisation to the right atrium represents less than 5% of the final destination of all such emboli (2). The most common destination of bullet emboli within the arterial system is the femoral artery. The main risk associated with venous emboli is pulmonary embolism, however arterial complications may still occur from right heart emboli if a patent foramen ovale is present. The incidence of patent foramen ovale in the general population is estimated at 25% (3). Emboli in the arterial system are symptomatic in 80% of cases compared to 33% of venous system cases (4).

Foreign bodies that embolise to and remain within the heart have been managed both conservatively and surgically in the literature (5). There may be a role for percutaneous intervention in some cases, however this has not been explored in detail. The presence of complications including endocarditis or arrhythmias may be an indication for intervention. Intra-cardiac emboli may be entrapped within endocardial trabeculations and with time can become encapsulated within fibrous tissue. The long-term risks of endocarditis or mural thrombus formation are not known.

CONCLUSION:
Foreign body embolisation should be considered in patients presenting with unexpected symptoms, signs or radiological findings following firearms injury. An echocardiogram should be performed for right heart emboli to exclude a patent foramen ovale due to the risk of arterial embolisation.

The authors have no conflicts of interest
Dr Matthew Arneill, Dr Claire Parris, Mr Richard Thompson, Mr Barry Clements.
Affiliation for all authors: Emergency Surgical Unit, Royal Victoria Hospital, Belfast. BT12 6BA
marneill01@qub.ac.uk
Correspondence to Matthew Arneill

REFERENCES:
1. Nolan T, Phan H, Hardy A, Khanna P, Dong P. Bullet embolization: multidisciplinary approach by interventional radiology and surgery. Semin Intervent Radiol. 2012; 29(3): 192–6.
2. Springer J, Newman W, McGoe R. Intravascular bullet embolism to the right atrium. J Forensic Sci. 2011;56 Suppl 1:S259-62.
3. Komar M, Podolec P, Przewlocki T, Wilkolek P, Tomkiewicz-Pajak L, Motyl R. Transoesophageal echocardiography can help distinguish between patients with “symptomatic” and “asymptomatic” patent foramen ovale. Kardiol Pol. 2012; 70(12):1258-63.
4. Michelassi F, Pietrabissa A, Ferrari M, Mosca F, Vargish T, Moosa H. Bullet emboli to the systemic and venous circulation. Surgery. 1990 107(3): 239-45.
5. Actis Dato GM, Arslanian A, Di Marzio P, Filosso PL, Ruffini E. Posttraumatic and iatrogenic foreign bodies in the heart: report of fourteen cases and review of the literature. J Thorac Cardiovasc Surg. 2003 126(2): 408-14.